Cxcr1 mediates recruitment of neutrophils and supports proliferation of tumor-initiating astrocytes in vivo

Davaly Powell1, Meng Lou1, Francisco Barros Becker1 & Anna Huttenlocher1,2

Neutrophils are first-responders to sites of infection and tissue damage and play an important role in host defense. Neutrophils also localize to the tumor microenvironment (TME) in a variety of human cancers and increased neutrophil infiltration and neutrophil-to-lymphocyte ratios in tumors often correlate with poor patient prognosis1. Therefore, there is increasing interest in understanding the role of neutrophils in the developing tumor microenvironment and how their presence alters adaptive immune responses. With recent advances in T-cell mediated immunotherapies, there is a need to better understand the role of innate leukocytes within the tumor and tumor-initiating niche, as well as the signals that mediate their recruitment to improve the efficacy of immunotherapy and patient outcomes.

Several recent studies have investigated the role of tumor-associated neutrophils (TANs) and how they influence the TME and cancer development (reviewed in2–4). For instance, there is evidence that neutrophils can modulate T cell tumoricidal activity by enhancing regulatory T cell recruitment and activity at the TME5,6. Neutrophils also secrete several factors including neutrophil elastase (NE), matrix metalloproteinases (MMPs), reactive oxygen species (ROS), vascular endothelial growth factor (VEGF), and others, which can modify the TME in favor of cancer cell growth and spread. On the other hand, an anti-tumor role for TANs has been reported in some models, and it is important to note that neutrophils exhibit phenotypic plasticity and heterogeneity which may contribute to a variety of effects in the TME5–10. Importantly, due to the constraints of available animal and cell culture models, few studies have investigated the role of neutrophils in early tumorigenesis or have identified signals that contribute to recruitment of neutrophils to tumor-initiating cells.

Neutrophils are highly migratory cells with the capacity to move within the blood stream and migrate interstitially to rapidly localize to sites of infection or injury. Several signaling pathways are involved in neutrophil chemotaxis and recruitment, many of which are also upregulated in the TME. One of the primary chemotactic pathways that regulates neutrophil migration is the CXCL8 (IL8)-CXCR1/2 pathway. In humans, CXCL8 is a chemokine which can be produced by many different cell types in response to various cytokines, ROS, pathogens,
and other environmental stresses\(^{11}\). Importantly, CXCL8 is conserved between human and zebrafish, but has not been identified in mice\(^{12}\). The primary receptors for CXCL8 are CXCR1 and CXCR2 which are expressed on the surface of neutrophils and regulate chemotaxis. CXCL8 is upregulated in many cancers including solid tumors (brain, breast, colon, gastric, lung, and others) and blood cancers (AML, CLL, Hodgkin’s lymphoma) and high levels of CXCL8 expression are often linked with disease progression\(^{13}\). CXCL8 can function in both a paracrine manner to alter the immune composition of the TME as well as in an autocrine manner to regulate tumor cell EMT and invasion\(^{14}\). The role of CXCL8 and its homologs in recruiting neutrophils to established tumors has been demonstrated in various Ras-driven cancer models\(^{15,16}\), however its role in recruiting neutrophils to tumor-initiating cells and the role of specific receptors is unclear.

To address the role of neutrophils and chemotactic signaling in the pre-tumor niche, we used an emerging cancer model system, the zebrafish larvae, to model glioblastoma initiation and progression. Glioblastoma is an aggressive cancer type originating from astrocytes and is marked by high levels of neutrophilic inflammation\(^{17}\) with high neutrophil-to-lymphocyte ratios and neutrophil activity correlating with enhanced tumor progression and poor patient outcomes\(^{18-20}\), however little is known about neutrophil interaction with early transformed astrocytes \textit{in vivo}. The zebrafish larval model allows for unparalleled non-invasive imaging of the early stages of tumor initiation as well as interactions between tumor-initiating cells and immune cells. Starting at 2 days post-fertilization (dpf), zebrafish larvae have a functional innate immune system comprising macrophages and neutrophils, however the adaptive immune system including B and T cells does not fully develop until approximately 2 weeks of development\(^{21-23}\). This early developmental window allows us to investigate the specific contribution of innate immune cells to the tumor-initiating niche. Using a transgenic model of glioblastoma initiation, we observed that neutrophils are highly recruited into the zebrafish hindbrain following expression of oncogenic Kras in astrocytes and that blocking neutrophil motility and function reduces the proliferative capabilities of Kras-expressing astrocytes. Additionally, we determined that the chemokine receptor Cxcr1 contributes to neutrophil recruitment into the tumor-initiating site while, similar to the wound microenvironment\(^{24}\), Cxcr2 is dispensable for neutrophil recruitment. Pharmacological inhibition of Cxcr1/2 reduces proliferation and mass formation within the brain. Altogether, these data suggest that the pro-neutrophil recruitment signaling axes, including Cxcl8-Cxcr1, are potential therapeutic targets of interest for glioblastoma and other inflammatory cancers.

**Materials and Methods**

**Zebrafish care and maintenance.** All adult and larval zebrafish were maintained according to protocols approved by the University of Wisconsin-Madison IACUC and in accordance with current guidelines and recommendations (ZFIn.org). Zebrafish embryos were treated with 0.003% phenylthiourea (PTU) in E3 media beginning at 24 hpf to prevent pigment formation. Zebrafish lines available via Zebrafish International Resource Center (ZIRC) include AB (wildtype), Tg(mpx:mCherry)\(^{\text{own}}\), Tg(mpx:mCherry:zdc\(\text{R557V})\(\text{Y307F}\), and Tp53\(^{\text{G57N}}\). Progeny from cxcr1 heterozygote in-cross were genotyped using the following primers and imaged on 3% MetaPhor agarose gel (7 bp deletion): cxcr1F: 5'-CCTGGTAGACTTCCAGGATGTCGCAGGTC 3', cxcr1R: 5'-TGAATATGTTGACGAGGCAGTCG 3'. As no significant difference was observed between WT and heterozygous siblings, these groups were combined for analysis of neutrophil recruitment and proliferation.

**Plasmid expression.** GFP-tagged human Kras\(^{\text{G12V}}\) or GFP alone was cloned under the ggap promoter (\(^{25}\) both gifts from Michael Taylor, UW-Madison) via Gateway (ThermoFisher) cloning into the pDest-to\(_2\) backbone. To generate WT controls, G12 point mutation was introduced via site-directed mutagenesis (QuikChange Lightning, Agilent) via the following primers: F: 5'- CACTCTTGGCTACGCCACGCTCACAATCCAC 3' and R 5'- GTGGTACTGCTGACGTCGAGTCG 3'. mCherry-tagged Histone H2B\(^{\text{G57N}}\) was cloned under the ggap promoter using the following primers: F 5'- AAGGCTAGACGATCTGTCGACGGTG 3' and R 5'- CTCGAGAAGGAATGCTGTTGACGAG 3'. 25–38 ng of plasmid DNA + 25 ng of transposase mRNA was injected into the single-cell stage embryo. Embryos were screened for fluorescent protein expression at 72 hours post-fertilization.

**Live imaging of zebrafish larvae.** For live imaging assays, zebrafish larvae were anesthetized at 3 dpf with 0.2 mg/mL Tricaine (MS222/ethyl 3-aminobenzoate; Sigma-Aldrich) in E3 media. For time-lapse imaging, larvae were mounted in 1% low-melting temperature agarose in E3 + Tricaine. Images were acquired by spinning disk confocal microscope (Yokogawa CSU-X) with a confocal scanhead on a Zeiss Observer Z.1 inverted microscope with NA 0.5/20\(\times\) objective. Z-stack acquisition was restricted to the hindbrain in the Z- (lateral) plane. Images were processed using ZEN software (ZEN 2.3 Blue) and analyzed using Fiji (image.net/Fiji). Maximum intensity projections are shown unless otherwise labeled.

**Characterization of morphology and quantification of neutrophil recruitment and proliferation.** To characterize transformed cell morphology, live imaging of Kras-expressing larval hindbrains was captured as above. ZEN software was used to analyze both maximum intensity projections and stacks for 3D morphology of GFP-positive cells. Larvae were categorized based on the most severe cell morphology observed in the hindbrain region (i.e. the presence of a single mass was categorized as “presence of masses”). To quantify neutrophil recruitment, live images of the hindbrain and surrounding tissue were acquired as above. mpx- :mCherry-positive neutrophils within the field of view were counted and then normalized to the GFP-positive area. GFP area was measured in Fiji using the Image > Adjust > Threshold function to manually remove background autofluorescence and the Analyze > Measure function. To quantify proliferation of tumor-initiating astrocytes, larvae were fixed and antibody stained as described below and then imaged via confocal microscopy similar
expressing wildtype Kras (Fig. 1A,B). Normal astrocytes within the zebrafish hindbrain exhibit a distinctive dor-

human KrasG12V under the zebrafish astrocyte-specific
we followed up on a published zebrafish model of glioblastoma that used the Gal4-UAS system to drive oncogenic

was exchanged with fresh E3 at 2.5 dpf in E3 with 0.02% DMSO for 16 hours prior to imaging. For drug treatments lasting until 6 dpf, media

was performed unless otherwise indicated; Chi-square analysis was performed for contingency analysis with a

across all replicates. Unpaired t-test plots, each dot refers to a single larva with all larvae (total n) reported across all replicates. Experimental conditions are plotted in terms of mean and 95% confidence interval. In scatter plots, each dot refers to a single larva with all larvae (total n) reported across all replicates. Unpaired t-test was performed unless otherwise indicated; Chi-square analysis was performed for contingency analysis with a Bonferroni correction for multiple comparisons. Statistical analyses and graphical representations were made in GraphPad Prism version 6.

Results

Zebrafish model of glioblastoma initiation. To investigate the role of neutrophils in tumor-initiation, we focused on 3 dpf, a time point by which neutrophils are mature and migrating interstitially throughout the head region adjacent to the hindbrain (Fig. 1A). Live imaging of larvae demonstrates that with expression of oncogenic KrasG12V, the morphology of astrocytes is altered compared to cells expressing GFP alone or cells expressing wildtype Kras (Fig. 1A,B). Normal astrocytes within the zebrafish hindbrain exhibit a distinctive dor-
al-ventral polarity and stellate morphology which is largely maintained in KrasWT-expressing cells. KrasG12V-expressing cells exhibit a loss of polarity, cell rounding, and occasionally the formation of large, multi-cellular masses (in ~13% of larvae). Co-expression of a construct encoding gfp-driven H2B-mCherry to label astrocyte nuclei further demonstrates the altered morphology and multi-cellular mass formation of KrasG12V-expressing cells (Fig. 1C). These changes in cell shape are accompanied by changes in gene expression. qRT-PCR of whole larvae revealed upregulation of EMT and adhesion genes including vimentin, mmp9, cdx1 (E-cadherin), and cdx2 (N-cadherin) at 3 dpf in gfp:KrasG12V-expressing larvae (Fig. 1D). In larvae which formed large masses by 6 dpf, N-cadherin-positive masses were also identified in a subset of larvae (<10%), consistent with EMT-like changes reported for glioblastoma32,33 (Fig. 1E). To further demonstrate oncogenic Kras-driven transformation of larval astrocytes, we assessed proliferation of KrasG12V-expressing cells. We performed whole mount immunofluorescent staining for proliferation marker phospho-histone H3 (pH3)34 in gfp:KrasG12V-expressing larval hindbrains at 3 dpf and imaged using confocal microscopy (Fig. 1F). Quantification of KrasG12V/pH3 double-positive cells was performed on optical sections revealing significantly increased proliferation of cells expressing oncogenic Kras (Fig. 1G). Counts were normalized to GFP-expression area in all experiments to account for the mosaic transformation pattern. At this developmental stage, non-GFP-KrasG12V positive proliferating cells (pH3-positive only) are also observed within the hindbrain, however no significant differences in this population of cells was observed between experimental groups (data not shown). These data suggest that as early as 3 dpf, KrasG12V drives oncogenic changes in zebrafish astrocytes which model early tumor-initiating events.

Neutrophils are recruited to the tumor-initiation niche. While neutrophils are frequently found in established tumors, their presence at sites of tumor initiation is less well characterized. In a zebrafish model of Hras-driven epithelial cell transformation, it was observed that neutrophils were recruited to transformed cells within 48 hours of Hras expression38. The zebrafish hindbrain, which is the site of astrocyte transformation in our model, is an excellent niche to study neutrophil recruitment since neutrophils are rarely found in uninfected or undamaged brain tissue. When KrasWT is expressed in astrocytes, neutrophil recruitment to the hindbrain, as observed by live imaging of neutrophil-specific mpz:mCherry transgenic larvae, is minimal (Fig. 2A,B). However, when KrasG12V is expressed, neutrophils are recruited to the brain and surrounding

to live-imaging experiments. In each acquired stack, cells which were both GFP and pH3 positive in optical sections were counted and then normalized to total GFP-positive area as described above.

Quantitative PCR and antibody staining. For qRT-PCR assays, 15–20 whole larvae per condition were pooled and placed in RNAlater (Ambion) at 4 °C for up to 2 weeks prior to mRNA isolation by Qiagen RNeasy Micro Kit and cDNA synthesis by SuperScript™ III First-Strand Synthesis System (ThermoFisher). qPCR was performed on a LightCycler 96 (Roche) using the FastStart Essential DNA Green Master kit (Roche) and previously published primers: rps11 (housekeeping gene), cxcl8a, cxcl8b, il1b27; vimentin, mmp928; and cdx1, cdx229. For whole mount antibody staining, larvae at 3 dpf were fixed with 1.5% formaldehyde in 0.1 M PIPES, 1.0 mM MgSO4, and 2 mM EGTA overnight at 4 °C as previously described30 and immunolabeled with 1:300 rabbit anti-phospho-Histone H3 antibody (Millipore 06–570) or rabbit anti-Cdh2 antibody (GeneTex GTX125885) in 1% BSA overnight at 4 °C followed by anti-rabbit secondary antibodies at 1:250 (DyLight734) in 1% BSA overnight at 4 °C. Stained larvae were imaged as above.

Morpholino-mediated knockdown. 3 nL of morpholino (Gene Tools) was injected into one-cell-stage embryos. Morpholino sequences and concentrations are as follows: standard control morpholino (5′-CTTCCACGTTCATATAACCA-3′, 100μM), ccr1 morpholino targeting the e1-i1 boundary (5′-TGTCAGGATAC TAAACTTACCAGTC-3′, 75μM)31.

Drug treatments. Dechorionated larvae were treated with 1μM SB225002 (Calbiochem; EMD Millipore) at 2.5 dpf in E3 with 0.02% DMSO for 16 hours prior to imaging. For drug treatments lasting until 6 dpf, media was exchanged with fresh E3 + SB225002 every 24 hours. Vehicle control samples were treated with 0.02% DMSO with daily media exchange.

Graphical representation and statistical analysis. All data comprise at least three independent experimental replicates unless otherwise noted, with n reported as total number of individual larvae analyzed across all replicates. Experimental conditions are plotted in terms of mean and 95% confidence interval. In scatter plots, each dot refers to a single larva with all larvae (total n) reported across all replicates. Unpaired t-test was performed unless otherwise indicated; Chi-square analysis was performed for contingency analysis with a Bonferroni correction for multiple comparisons. Statistical analyses and graphical representations were made in GraphPad Prism version 6.
microenvironment at 3 dpf. Live, time-lapse imaging of the hindbrain demonstrates dynamic trafficking of neutrophils into the tumor-initiating and surrounding microenvironments, resulting in prolonged neutrophil recruitment in gfap:KrasG12V-expressing larvae (Fig. 2C, Supplemental Movies 1–2). Interestingly, neutrophils are rarely observed to pause within the tumor-initiating microenvironment and do not appear to directly contact transformed cells for any notable period of time. To determine which pathways might be involved in neutrophil recruitment to the tumor-initiating microenvironment, we performed qRT-PCR for several inflammatory cytokines. We determined that gfap:KrasG12V results in an upregulation of the pro-inflammatory cytokine il1b (IL-1β) as well as the neutrophil chemokines cxcl8a (IL-8a) and cxcl8b (IL-8b) at 3 dpf (Fig. 2D). These results
suggest that the tumor-initiating microenvironment produces inflammatory signals that recruit neutrophils at very early stages during transformation.

**Neutrophil recruitment to the tumor-initiating microenvironment enhances proliferation of transformed cells.** To determine the effect of neutrophil recruitment on tumor-initiation, we employed previously characterized zebrafish models of impaired neutrophil migration and function and characterized early proliferation of transformed astrocytes. We first used whole larvae morpholino-mediated knockdown of the small Rho-GTPase, Rac2, which is required for neutrophil motility and recruitment to sites of tissue injury and infection in zebrafish larvae. We co-injected the rac2 morpholino (MO) with gfap:GFP-Kras G12V into Tg(mpx:mCherry) larvae and assessed neutrophil recruitment to the hindbrain. As expected, at 3 dpf, neutrophil recruitment to the hindbrain was almost completely ablated in rac2 knockdown larvae, demonstrating efficacy of this model in preventing neutrophil migration to the site of tumor-initiation (Fig. 3A,B). We next assayed for transformed cell proliferation following rac2 knockdown. Interestingly, in the rac2 knockdown, Kras G12V-expressing astrocytes exhibited significantly reduced proliferation compared to controls (Fig. 3C,D). To determine if this result was due to rac2 regulating neutrophil motility or through transformed cell-intrinsic effects, we used neutrophil-specific expression of a dominant-negative Rac2 mutation, mpx:Rac2D57N, which similarly blocks neutrophil recruitment into tissues. As seen in the whole-larvae knockdown, neutrophils were unable to migrate into the hindbrain of gfap:Kras G12V-expressing larvae (Fig. 3E,F). pH3 staining in the mpx:Rac2D57N larvae also revealed that the transformed cells exhibited reduced proliferation in the absence of neutrophil infiltration into the microenvironment (Fig. 3G,H). These data demonstrate that neutrophil recruitment and presence in the tumor-initiating environment enhances the proliferation of tumor-initiating cells within the brain.

**Chemokine signaling through Cxcr1 promotes neutrophil recruitment to the tumor-initiating microenvironment.** As our data indicate that neutrophils support proliferation of transformed astrocytes, we next sought to investigate the signals responsible for neutrophil recruitment to the tumor-initiating niche. Our previous data showed that IL-8 family chemokines were upregulated with expression of oncogenic Kras in the brain (Fig. 2D), and similarly, IL-8 is upregulated in human glioblastoma. We have also previously shown that zebrafish Cxcr1 is required for neutrophil recruitment to sterile wounds but not to infection and is dispensable for normal neutrophil development and random motility. Therefore, we characterized the role of the IL-8 receptor Cxcr1 in regulating neutrophil recruitment to tumor-initiating cells. We injected gfap:GFP-Kras G12V in wildtype, cxcr1 +/+ , or cxcr1 −/− embryos expressing mpx:mCherry and then analyzed neutrophil recruitment to the hindbrain at 3 dpf (Fig. 4A). Similar to what was observed in the wound microenvironment, we found that significantly fewer neutrophils were recruited to the hindbrain and surrounding tissue in cxcr1 mutants compared to wildtype and cxcr1 heterozygote siblings (Fig. 4B). Intriguingly, in mutants for the related receptor Cxcr2, we did not observe any decrease in neutrophil recruitment to transformed astrocytes (Figure S1), further suggesting the tumor-initiating microenvironment is similar to the wound neutrophil chemotactic microenvironment.

**Figure 2.** Neutrophils are recruited to the tumor-initiating microenvironment. Live-imaging of neutrophils in the hindbrain of Tg(mpx:mCherry) larvae expressing gfap:kras WT or kras G12V at 3 dpf (A). Neutrophils within the field of view were quantified and normalized to the total gfap-expressing area within the same field of view at 3 and 6 dpf (B, n = 24 kras WT 3dpf, 42 kras G12V 3 dpf, 24 kras WT 6 dpf, and 30 kras G12V 6 dpf larvae). Live time-lapse imaging was performed for 9 hours beginning at 3–3.5 dpf and total neutrophils recruited to the hindbrain during the period of imaging were quantified (C, n = 9 kras WT and 11 kras G12V larvae). qRT-PCR was performed on whole-larvae mRNA isolates for several neutrophil recruiting chemokines implicated in the tumor microenvironment including cxc8a, cxc8b, and il1b (D, n = 6 replicates for cxc8a/b, 5 replicates for il1b, normalized as in Fig. 1D). *p < 0.05.
To determine if this recruitment mechanism could also be blocked by pharmacological inhibition, we used SB225002, an inhibitor of Cxcr1 and Cxcr2. In comparison to vehicle control, SB225002 treatment resulted in significantly fewer neutrophils recruited to the hindbrain of larvae expressing \textit{gfap}:Kras\textsuperscript{G12V} (Fig. 4C,D) thus...

**Figure 3.** Blocking neutrophil motility reduces proliferation of tumor-initiating cells. Wildtype or Tg(\textit{mpx}:mCherry) embryos were co-injected with \textit{gfap}:GFP-Kras\textsuperscript{G12V} plasmid and \textit{rac2} or standard control morpholino (MO). Larvae were live-imaged for neutrophil recruitment at 3 dpf (A) and quantified for neutrophils within the field of view normalized to GFP-expression area (B, n = 13 control MO and 18 \textit{rac2} MO larvae). Larvae were also fixed at 3 dpf and immunostained for phospho-Histone H3 (C). Double-positive (pH3 and GFP) cells were quantified by optical sectioning and normalized as above (D, yellow arrowheads in C, n = 21 control MO and 17 \textit{rac2} MO larvae). Tg(\textit{mpx}:mCherry-2a-Rac2\textsuperscript{WT}) or Tg(\textit{mpx}:mCherry-2a-Rac2\textsuperscript{D57N}) embryos were injected with \textit{gfap}:GFP-Kras\textsuperscript{G12V} and live-imaged at 3 dpf (E). mCherry-positive neutrophils were quantified and normalized as above (F, n = 52 Rac2\textsuperscript{WT} and 46 Rac2\textsuperscript{D57N} larvae). Larvae were fixed at 3 dpf and immunostained for phospho-Histone H3 (G). pH3-GFP double positive cells were quantified by optical section and normalized as above (H, n = 30 Rac2\textsuperscript{WT} and 37 Rac2\textsuperscript{D57N} larvae). *p < 0.05.
recapitulating the Cxcr1 mutant phenotype. Additionally, transient knockdown of cxcr1 with splice-blocking morpholino similarly reduced neutrophil recruitment to the hindbrain (Fig. 4E,F). In a related model of epithelial cell transformation in which Kras G12V was transiently expressed in larval zebrafish keratinocytes, neutrophil recruitment was also reduced upon knockdown of cxcr1 (data not shown). These data demonstrate the requirement of Cxcr1 signaling, but not Cxcr2, in neutrophil trafficking to the tumor-initiating microenvironment, similar to the wound microenvironment.

Cxcr1/2 inhibition reduces proliferation and progression of tumor-initiating astrocytes. We next investigated the effect of Cxcr1/2 inhibition on the proliferation of tumor-initiating astrocytes. Similar to what we observed in larvae with impaired neutrophil motility, we observed a significant reduction in proliferating Kras-positive astrocytes in cxcr1 mutant larvae compared to wildtype or heterozygous siblings (Fig. 5A,B). Importantly, we observed the same phenotype upon pharmacological inhibition of Cxcr1/2 signaling with SB225002 treatment. In gfp:GFP-kras G12V, expressing larvae treated with SB225002, proliferation of transformed astrocytes was significantly reduced compared to vehicle control (Fig. 5C,D). To determine if the reduction
in proliferation observed in the SB225002-treated larvae was attributable primarily to neutrophil loss in the tumor-initiating microenvironment, we next treated neutrophil-specific Rac2 D57N mutants with SB225002 or DMSO control. At 3 dpf, no additive effect was observed in Rac2 D57N mutants treated with SB225002 compared to DMSO controls (Figure S2), suggesting that the proliferation reduction observed in SB225002 is primarily due to the lack of neutrophils in the microenvironment and not due to other cell types within the microenvironment or astrocyte-intrinsic effects. These data demonstrate that Cxcr1/2 promotes proliferation of tumor-initiating astrocytes and suggests that this proliferation is due to Cxcr1/2-mediated neutrophil recruitment.

Oncogenic Kras induces neoplastic masses in p53−/− larvae which requires Cxcr1/2 signaling. To determine the effect of Cxcr1/2 signaling on the outcome of transformed cells, we turned to the more tumor-permissive p53 mutant background which allows for heightened progression of disease in other zebrafish cancer models. We found that p53−/− larvae expressing gfap:krasG12V exhibit more advanced tumor-initiation at 3 and 6 dpf with a higher proportion of larvae demonstrating cell rounding and mass formation compared to the wildtype background (Fig. 6A,B). Importantly, recruitment of neutrophils to these masses was normal compared to wildtype background, as was neutrophil migration to a tail-fin wound, suggesting that p53 mutants have normal neutrophil motility and behavior (Figure S3). This enhanced and more rapid mass growth in the p53 mutants allowed us to assay whether blocking neutrophil chemotaxis to the tumor-initiating niche affects early tumorigenesis beyond proliferation. p53 mutant larvae expressing gfap:krasG12V were treated with the Cxcr1/2 inhibitor SB225002 starting at 2.5 dpf, with drug or vehicle refreshment every 24 hours, and imaged on 3 dpf and 6 dpf for astrocyte morphology (Fig. 6C,D). As expected based on the reduced proliferation of transformed cells observed in SB225002-treated WT larvae, mass formation was also significantly reduced when Cxcr1/2 was blocked in p53 mutants (Fig. 6D,E). Concurrently, a higher proportion of transformed astrocytes exhibited less severe morphology of altered polarity, demonstrating that while blocking Cxcr1/2 signaling is not able to fully restore KrasG12V-expressing cells to their normal, wildtype morphology, it does appear to inhibit progression to more advanced stages of cellular transformation. Similarly, mass number was significantly inhibited in SB225002-treated p53−/− larvae with almost no larvae developing 2 or more masses compared to approximately 20% of control-treated larvae (Fig. 6F). Additionally, in the larvae that developed masses, the average mass size was significantly decreased in SB225002-treated larvae compared to controls (Fig. 6G). Altogether, these data suggest that blocking Cxcr1/2 inhibits tumor initiation and progression of neoplastic astrocytes in vivo, further supporting a role for Cxcr1 signaling at the tumor-forming niche.

Figure 5. Blocking neutrophil chemotaxis signaling reduces proliferation of tumor-initiating cells. cxc1 heterozygote fish were in-crossed, injected with gfap:krasG12V, fixed for pH3 immunostaining at 3 dpf, and genotyped post-imaging as described above (A). pH3-GFP double-positive cells were quantified and normalized as in previous figures (B, yellow arrowheads in A, n = 19 WT/het and 26 cxc1−/− larvae). Wildtype larvae expressing gfap:krasG12V were treated with 1 µM SB225002 or DMSO control as described in Fig. 4. Larvae were fixed at 3 dpf and immunostained for phospho-Histone H3 (C). Proliferating cells were quantified as above (D, double-positive cells marked by yellow arrowhead in C, n = 17 larvae/condition). *p < 0.05.
Discussion

Here we demonstrate that neutrophils play a tumor-promoting role in the early tumor microenvironment within the brain using transparent zebrafish larvae. In this model of glioblastoma initiation, we show that neutrophils are actively recruited to tumor-initiating cells very early in oncogenesis. The presence of neutrophils within the microenvironment enhances proliferation of oncogene-transformed cells. We demonstrate a role for the chemokine receptor Cxcr1 in the neutrophil response to transformed astrocytes. Interestingly, Cxcr2 does not appear to be required for neutrophil recruitment to the tumor-initiating microenvironment, suggesting that neutrophil response to the early TME is more like their response to wounds than infected tissue \(^24,31\). We also find that pharmacological inhibition of the Cxcr1/2 signaling pathway decreases neutrophil recruitment, reduces early proliferation of tumor-initiating cells, and reduces subsequent pre-tumorous mass formation in a \(p53\) null background.

A role for the IL8-CXCR1/2 signaling axis has been previously demonstrated in cancer and other inflammatory diseases\(^11\). Specifically in glioma, high expression of CXCR2 correlates with high-grade glioma in patients, poor prognosis, and tumor recurrence, while inhibition of CXCR1/2 signaling with the SB225002 inhibitor reduced migration of glioma cells \(in vitro\)\(^41\). Here, we show that in addition to tumor cell-intrinsic roles for Cxcr1/2, this signaling pathway is also crucial for recruitment of neutrophils into the tumor-initiating microenvironment which then supports proliferation of transformed cells. Indeed, we observed no additive effect of Cxcr1/2 inhibition on proliferation in neutrophil-deficient lines, suggesting that Cxcr1/2 inhibition primarily affects transformed astrocyte proliferation via effects on neutrophils rather than through astrocyte-intrinsic pathways in this model. Importantly, pharmacological inhibitors of CXCR1/2 are already in clinical trials for several inflammatory diseases including COPD, asthma, and rheumatoid arthritis as well as for certain cancers including breast cancer and melanoma\(^11,42\).

Figure 6. Inhibition of neutrophil chemotaxis reduces early mass formation in \(p53\) mutant larvae. Morphology of \(gfap\)-GFP-kras\(^{G12V}\) expressing astrocytes in WT or \(p53\) mutant background at 3 and 6 dpf (A, \(n = 87\) WT 3 dpf, 113 \(p53^{-/-}\) 3 dpf, 75 WT 6 dpf, and 99 \(p53^{-/-}\) 6 dpf larvae; Chi-squared analysis performed). The percentage of larvae developing masses at 6 dpf is shown in (B). \(p53\) mutant embryos were injected with \(gfap\)-GFP-kras\(^{G12V}\) plasmid and treated with DMSO control or 1uM SB225002 beginning at 2.5 dpf with drug refreshed every 24 hrs. Larval hindbrain was live-imaged at 3 dpf and 6 dpf (6 dpf shown in (C), asterisks denote masses). Morphology of GFP-expressing cells was categorized as described in Fig. 1B (D, \(n = 84\) DMSO 3 dpf, 88 SB225002 3 dpf, 39 DMSO 6 dpf, and 50 SB225002 6 dpf larvae; Chi-squared analysis performed). Average number of masses was quantified in all larvae at 6 dpf (E, \(n = 40\) DMSO and 50 SB225005 larvae). Larvae were also categorized by number of masses formed (0, 1, or \(\geq 2\)) by 6 dpf (F) and in larvae with masses present, average mass size (\(\mu m^2\)) was measured (G, \(n = 29\) DMSO and 15 SB225002 larvae). *\(p < 0.05\) For Supplementary Figure Legends, please see Supplementary Information file.
Previous data from our lab suggests that Cxcr1 is specifically required for neutrophil recruitment to sites of sterile tissue damage and is dispensable for recruitment to infection. This type of specificity for the TME and not for infected tissue is particularly useful for cancer patients since chemotherapy-related neutropenia increases infection risk in these patients. Our data suggest that specific inhibition of CXCR1 may be a potential target of interest in glioblastoma and other tumor types that are characterized by high levels of neutrophil infiltration or alternatively as a potential prophylactic measure for patients at high risk of developing inflammation-associated cancers. It is interesting that the other zebrafish Cxcli receptor Cxcr2 was not required for recruitment to transformed astrocytes, although it is necessary for neutrophil recruitment to infection. These findings support the TME as a type of "unhealed wound" with the involvement of similar environmental cues and receptors that mediate neutrophil infiltration. Recently, mouse Cxcr2 was demonstrated to play a role in neutrophil accumulation within the tumor as well as T cell infiltration and tumor metastasis. Interestingly, the zebrafish model suggests that neutrophils can play a role in tumor progression independent of T cells. It is also important to note that it is unclear whether zebrafish Cxcr1 and Cxcr2 are functionally homologous to their mammalian orthologs. Evidence suggests that in zebrafish, Cxcr1 and Cxcr2 play distinct roles in regulating neutrophil recruitment to different tissue insults. Whether these distinct roles are conserved in humans remains unclear.

Tumor associated neutrophils are an intriguing target for the treatment of human cancer. In humans, neutrophils have been implicated in cancer progression in several cancers. Our data suggest that neutrophils can support proliferation of early tumor-initiating astrocytes. These findings are consistent with the idea that chronic neutrophil inflammation can lead to increased risk of developing cancer. One explanation for how neutrophil exert their effect is that neutrophils produce reactive oxygen and nitrogen species (ROS and RNS) which can cause DNA damage and may induce oncogenesis in nearby cells. Our data suggest that, in addition, the presence of neutrophils promotes proliferation of transformed cells in the brain. Our findings are consistent with previous studies which have demonstrated that in zebrafish models of skin oncogenesis, neutrophil recruitment enhances proliferation and EMT of transformed cells. One of the potential mechanisms for this interaction is through the production of neutrophil elastase (NE), which has been shown to enhance proliferation of cancer and other cell types in culture. Indeed, inhibitors of NE have previously been suggested as potential anti-cancer therapeutic targets by several groups. In addition to their demonstrated role in the primary TME, neutrophils have also been implicated in priming the metastatic niche for secondary tumor growth. Our data suggest that targeting neutrophil chemotaxis and tumor infiltration could provide a useful avenue for developing future clinical targets. One exciting new approach is exploiting neutrophils' highly migratory and tumor-infiltrative capabilities to target drugs to the TME. In a recent study by Xue et al., primary mouse neutrophils loaded with liposomes containing paclitaxel were injected into the blood stream of a glioma mouse model post-tumor resection, resulting in neutrophil homing to the brain, release of the drug, and ultimately increased survival in treated mice. Further understanding of the signals and receptors which enhance neutrophil recruitment into the TME could allow the engineering of drug-delivering neutrophils with even greater TME homing and tumoricidal efficacy.

There is some controversy over whether TANs are generally tumor-promoting or whether they can also play a role in killing and clearance of tumor cells. There is evidence that, similar to macrophages, neutrophils can be polarized into an anti-tumor N1 or pro-tumor N2 phenotype depending on signals from the microenvironment such as TGF-. There are also several subpopulations of neutrophils that display a variety of characteristics and phenotypes which likely can contribute to a heterogeneity of TAN behavior and impact. Exposure to the TME itself may also influence neutrophil plasticity and polarization, adding further complexity to understanding the role of neutrophils in cancer progression. Importantly, little is known about how chemotactic signaling receptors are regulated throughout neutrophil recruitment and plasticity in response to tumor formation and if different neutrophil subpopulations employ different pathways to regulate and direct their migration. Further study is needed to determine the migratory mechanisms and behavior of tumor-activated neutrophils, as well as their role in cancer progression in a variety of cancer types to inform future therapies to treat human cancer.

Data Availability Statement

All data generated or analysed during this study are included in this published article (and its Supplementary Information files). No datasets were generated or analysed during the current study.

References

1. Faria, S. S. et al. The neutrophil-to-lymphocyte ratio: a narrative review. Eura. cancer 10, 702, https://doi.org/10.3332/eccancer.2016.702 (2016).
2. Powell, D. R. & Huttonlocher, A. Neutrophils in the Tumor Microenvironment. Trends in immunology 37, 41–52, https://doi.org/10.1016/j.it.2015.11.008 (2016).
3. Coffelt, S. B., Wölffenstein, M. D. & de Visser, K. E. Neutrophils in cancer: neutral no more. Nature reviews. Cancer 16, 431–446, https://doi.org/10.1038/nrc.2016.52 (2016).
4. Ocana, A., Nieto-Jimenez, C., Pandiella, A. & Templeton, A. J. Neutrophils in cancer: prognostic role and therapeutic strategies. Mol Cancer 16, 137, https://doi.org/10.1186/s12943-017-0707-7 (2017).
5. Galderio, M. R., Varricchi, G., Loffredo, S., Mantovani, A. & Marone, G. Roles of neutrophils in cancer growth and progression. Journal of leukocyte biology, https://doi.org/10.1002/jlb.3MR0717-292R (2017).
6. Mishalain, I. et al. Neutrophils recruit regulatory T-cells into tumors via secretion of CCL17—a new mechanism of impaired antitumor immunity. International journal of cancer 135, 1178–1186, https://doi.org/10.1002/ijc.28779 (2014).
7. Zhou, S. L. et al. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib. Gastroenterology 150, 1646–1658 e1617, https://doi.org/10.1053/j.gastro.2016.02.040 (2016).
8. Fridlender, Z. G. et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: “N1” versus “N2” TAN. Cancer cell 16, 183–194, https://doi.org/10.1016/j.ccr.2009.06.017 (2009).
9. Fridlender, Z. G. et al. Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils. PloS one 7, e31524, https://doi.org/10.1371/journal.pone.0031524 (2012).

10. There are also several subpopulations of neutrophils that display a variety of characteristics and phenotypes which likely can contribute to a heterogeneity of TAN behavior and impact. Exposure to the TME itself may also influence neutrophil plasticity and polarization, adding further complexity to understanding the role of neutrophils in cancer progression. Importantly, little is known about how chemotactic signaling receptors are regulated throughout neutrophil recruitment and plasticity in response to tumor formation and if different neutrophil subpopulations employ different pathways to regulate and direct their migration. Further study is needed to determine the migratory mechanisms and behavior of tumor-activated neutrophils, as well as their role in cancer progression in a variety of cancer types to inform future therapies to treat human cancer.
10. Sagiv, J. Y. et al. Phenotypic diversity and plasticity in circulating neutrophil subpopulations in cancer. Cell reports 10, 562–573, https://doi.org/10.1016/j.celrep.2014.12.039 (2015).

11. Ha, H., Debnath, B. & Neumati, N. Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases. Theranostics 7, 1543–1588, https://doi.org/10.7150/thno.15625 (2017).

12. Oehlerls, S. H. et al. Expression of zebrafishicx8 (interleukin-8) and its receptors during development and in response to immune stimulation. Developmental and comparative immunology 34, 352–359, halutzatutoro.1016/j.dci.2009.11.007 (2010).

13. Xie, K. Interleukin-8 and human cancer biology: Cytokine Growth Factor Rev 12, 375–391 (2001).

14. Long, X. et al. IL-8, a novel messenger to cross-link inflammation and tumor EMT via autocrine and paracrine pathways (Review). Int J Oncol 48, 5–12, https://doi.org/10.3892/ijo.2015.3234 (2016).

15. Sparmann, A. & Bar-Sagi, D. Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer cell 6, 447–458, https://doi.org/10.1016/j.ccr.2004.09.028 (2004).

16. H. H. et al. K-ras activation generates an inflammatory response in lung tumors. Oncogene 25, 2105–2112, https://doi.org/10.1038/sonc.2006.292 (2006).

17. Fossati, G. et al. Neutrophil infiltration into human gliomas. Acta neuropathologica 98, 349–354 (1999).

18. Lopes, M., Carvalho, B., Vaz, R. & Linhares, P. Influence of neutrophil-lymphocyte ratio in prognosis of glioblastoma multiforme. Journal of neuro- oncology 136, 173–180, https://doi.org/10.1007/s11060-017-2641-1 (2018).

19. Rahbar, A. et al. Enhanced neutrophil activity is associated with shorter disease-free and tumor progression in glioblastoma patients. Oncoinmuneology 5, e1075693, https://doi.org/10.1080/2162420X.2015.1075693 (2016).

20. Han, S. et al. Pre-treatment neutrophil-to-lymphocyte ratio is associated with neutrophil and T-cell infiltration and predicts clinical outcome in patients with glioblastoma. BMC cancer 15, 617, https://doi.org/10.1186/s12943-015-0288-2 (2015).

21. Lam, S. H., Chua, H. L., Gong, Z., Lam, T. J. & Sin, Y. M. Development and maturation of the immune system in zebrafish, Danio rerio: a gene expression profiling, in situ hybridization and immunological study. Developmental and comparative immunology 28, 9–28 (2004).

22. Willett, C. E., Cortes, A., Zuasti, A. & Zapata, A. G. Early hematopoiesis and developing lymphoid organs in the zebrafish. Developmental biology 201, 249–254, https://doi.org/10.1016/j.cub.2005.01.031 (2005).

23. Van Meir, E. et al. Interleukin-8 is produced in neoplastic and infectious diseases of the human central nervous system. Cancer research 52, 4297–4305 (1992).

24. Berghmans, S. et al. tp53 mutant zebrafish develop malignant peripheral nerve sheath tumors. Proceedings of the National Academy of Sciences of the United States of America 102, 407–412, https://doi.org/10.1073/pnas.0406252102 (2005).

25. Gutierrez, A. et al. Aberrant AKT activation drives well-differentiated liposarcoma. Proceedings of the National Academy of Sciences of the United States of America 108, 16386–16391, https://doi.org/10.1073/pnas.1106127108 (2011).

26. Patton, E. E. et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Current biology: CB 15, 249–254, https://doi.org/10.1016/j.cub.2005.01.031 (2005).

27. Dovey, M., White, R. M. & Zon, L. I. Oncogenic NRAS cooperates with p53 loss to generate melanoma in zebrafish. Zebrafish 6, 397–404, https://doi.org/10.1089/zeb.2009.0060 (2009).

28. Lang, L. et al. Correlation of C-X-C chemokine receptor 2 upregulation with poor prognosis and recurrence in human glioma. Oncol Targets Ther 8, 3203–3209, https://doi.org/10.2147/OTT.S91626 (2015).

29. ClinicalTrials.gov. (2018).

30. Crawford, J., Dale, D. C. & Lyman, G. H. Chemotherapy-induced neutropenia: risks, consequences, and new directions for its management. Cancer 100, 228–237, https://doi.org/10.1002/cncr.11882 (2004).

31. Steele, C. W. et al. CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. Cancer cell 29, 832–845, https://doi.org/10.1016/j.ccel.2016.04.014 (2016).

32. Coussens, L. M. & Werb, Z. Inflammation and cancer. Nature 420, 860–867, https://doi.org/10.1038/nature01322 (2002).

33. Multhoff, G., Molis, M. & Radons, J. Chronic inflammation in cancer development. Frontiers in immunology 2, 98, https://doi.org/10.3389/fimmu.2011.00098 (2011).

34. Peng, Y., Santorielo, C., Mione, M., Hurlstone, A. & Martin, P. Live imaging of innate immune cell sensing of transformed cells in zebrafish larvae: parallels between tumor initiation and wound inflammation. PLoS biology 8, e1000562, https://doi.org/10.1371/journal.pbio.1000562 (2010).

35. Yan, C., Hua, X., Wang, S., Feng, Y. & Gong, Z. Stimulation of hepatocarcinogenesis by neutrophils upon induction of oncogenic kras expression in transgenic zebrafish. Journal of hepatology 63, 420–428, https://doi.org/10.1016/j.jhep.2015.03.024 (2015).

36. Gregory, A. D. et al. Neutrophil elastase promotes myofibrolast differentiation in lung fibrosis. Journal of leukocyte biology 98, 143–152, https://doi.org/10.1189/jlb.3HI014-4938R (2015).

37. Wada, Y. et al. Neutrophil elastase induces cell proliferation and migration by the release of TGF-alpha, PDGF and VEGF in esophageal cell lines. Oncology reports 17, 161–167 (2007).

38. Gutierrez, A. The role of interleukin-8, its receptors and analogues in cancer progression. Developmental and comparative immunology 28, 1009–1016 (2004).
51. Yang, R. et al. Neutrophil elastase enhances the proliferation and decreases apoptosis of leukemia cells via activation of PI3K/Akt signaling. *Mol Med Rep* **13**, 4175–4182, https://doi.org/10.3892/mmr.2016.5051 (2016).
52. Yang, X. et al. Neutrophil elastase promotes proliferation of HaCaT cell line and transwell psoriasis organ culture model. *Int J Dermatol* **49**, 1068–1074, https://doi.org/10.1111/j.1365-4632.2010.04500.x (2010).
53. Xu, Y. et al. Curcumin inhibits tumor proliferation induced by neutrophil elastase through the upregulation of alpha1-antitrypsin in lung cancer. *Mol Oncol* **6**, 405–417, https://doi.org/10.1016/j.molonc.2012.03.005 (2012).
54. Caruso, J. A., Hunt, K. K. & Keyomarsi, K. The neutrophil elastase inhibitor elafin triggers rb-mediated growth arrest and caspase-dependent apoptosis in breast cancer. *Cancer research* **70**, 7125–7136, https://doi.org/10.1158/0008-5472.CAN-10-1547 (2010).
55. Kumagai, K. et al. The neutrophil elastase inhibitor sivelestat suppresses accelerated gastrointestinal tumor growth via peritonitis after cecal ligation and puncture. *Anticancer Res* **33**, 3653–3659 (2013).
56. Nawa, M. et al. Growth effect of neutrophil elastase on breast cancer: favorable action of sivelestat and application to anti-HER2 therapy. *Anticancer Res* **32**, 13–19 (2012).
57. Wada, Y. et al. Sivelestat, a specific neutrophil elastase inhibitor, suppresses the growth of gastric carcinoma cells by preventing the release of transforming growth factor-alpha. *Cancer Sci* **97**, 1037–1043, https://doi.org/10.1111/j.1349-7006.2006.00278.x (2006).
58. Jablonska, J., Lang, S., Sonov, R. V. & Granot, Z. The regulation of pre-metastatic niche formation by neutrophils. *Oncotarget* **8**, 112132–112144, https://doi.org/10.18632/oncotarget.22792 (2017).
59. Xue, J. et al. Neutrophil-mediated anticancer drug delivery for suppression of postoperative malignant glioma recurrence. *Nature nanotechnology* **12**, 692–700, https://doi.org/10.1038/nnano.2017.54 (2017).
60. Mishalian, I. et al. Tumor-associated neutrophils (TAN) develop pro-tumorigenic properties during tumor progression. *Cancer immunology, immunotherapy: CII* **62**, 1745–1756, https://doi.org/10.1007/s00262-013-1476-9 (2013).

**Acknowledgements**

The authors thank Michael Taylor (UW-Madison) for gifting plasmids required for creation of the zebrafish model of glioblastoma initiation and Emily Rosowski, Veronika Miskolci, Sofia de Oliveira, and Laurel Hind for thoughtful reading and editing of the manuscript. D.P. is supported by the Irvington Postdoctoral Fellowship from the Cancer Research Institute, M.L. is supported by the UW-Madison Hilldale Undergraduate Research Fellowship, and A.H. is supported by NCI CA085862.

**Author Contributions**

Experiments were designed by D.P. and A.H., performed by D.P., M.L. and F.B., and data analyzed by D.P. and M.L. Manuscript was written and edited by D.P. and A.H.

**Additional Information**

Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-31675-0.

**Competing Interests:** The authors declare no competing interests.

**Publisher’s note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

**Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2018